On Thursday, ITT Educational Services, Inc. (NYSE:ESI)’s shares declined -12.73% to $5.28.
ITT Educational Services, Inc. (ESI) declared that Daniel M. Fitzpatrick notified the Company of his plan to retire from his positions of Executive Vice President and Chief Financial Officer of the Company. Following Mr. Fitzpatrick’s notice, the Company reached a letter agreement with Mr. Fitzpatrick on April 29, 2015, following which Mr. Fitzpatrick will remain in his current positions until October 29, 2015 (the “Transition Period”). The Company may extend the Transition Period by up to four months and may terminate it at any time upon notice to Mr. Fitzpatrick. In addition, during the Transition Period, the Company is permitted to change Mr. Fitzpatrick’s role to that of Senior Advisor. It is predictable that Mr. Fitzpatrick will become a consultant to the Company for a period of 18 months following the Transition Period. Mr. Fitzpatrick has served as the Company’s Chief Financial Officer since 2005
ITT Educational Services, Inc. provides postsecondary degree programs in the United States. It offers master, bachelor, and associate degree programs to about 57,000 students, in addition to short-term information technology and business learning solutions for career advancers and other professionals.
QuickLogic Corporation (NASDAQ:QUIK)’s shares dropped -12.44% to $1.76.
QuickLogic Corporation (QUIK) declared the financial results for its Fiscal first quarter ended March 29, 2015.
Total revenue for the first quarter of 2015 was $6.2 million, representing an enhance of 8% contrast to $5.7 million in the fourth quarter of 2014 and a decrease of 45% contrast to $11.2 million in the first quarter of 2014. New product revenue for the first quarter of 2015 was $4.1 million, an enhance of 13% contrast to $3.7 million in the fourth quarter of 2014 and a decrease of 54% contrast to $8.9 million in the first quarter of 2014. During the first quarter, mature product revenue was $2.0 million which was flat sequentially and down 10% as contrast to the first quarter of 2014. New product revenue accounted for 67% of the total revenue in the first quarter of 2015 contrast to 64% in the fourth quarter of 2014 and 80% in the first quarter of 2014.
QuickLogic Corporation, a fabless semiconductor company, develops and markets low power customizable semiconductor and software algorithm solutions for tablets, wearables, smartphones, and mobile enterprise markets.
At the end of Thursday’s trade, On Assignment, Inc. (NYSE:ASGN)‘s shares dipped -11.07% to $33.65.
On Assignment, Inc. (ASGN) stated results for the quarter ended March 31, 2015. Operating results of the Physician Segment, which was sold effective February 1, 2015, are comprised of in suspended operations for all periods presented.
First Quarter Highlights
- Revenues were $430.0 million; up 5.7 percent year-over-year (6.7 percent on a constant currency basis). Adverse effect of inclement weather on revenues was about $4.5 to $5.5 million ($2.0 million higher than previous estimates) and foreign currency exchange rates adversely affected revenues $0.9 million more than predictable.
- Adjusted income from ongoing operations (a non-GAAP measure defined below) was $21.6 million ($0.41 per diluted share).
On Assignment, Inc. provides short- and long-term placement of contract, contract-to-hire, and direct hire professionals in the United States, Europe, Canada, Australia, and New Zealand. The company operates in four segments: Apex, Oxford, Physician, and Life Sciences Europe.
TESARO Inc (NASDAQ:TSRO), ended its Thursday’s trading session with -10.79% loss, and closed at $54.47.
TESARO Inc (TSRO) offered an update on its niraparib clinical development program. The targeted enrollment has been achieved in both patient cohorts of the Phase 3 NOVA trial of niraparib, and TESARO anticipates data from NOVA in the fourth quarter of 2015. In addition, the QUADRA treatment trial of niraparib has been initiated, and initial data from this trial is anticipated in early 2016.
TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
